Inventor · disambiguated record
Jason D. Speake
Also filed as: SPEAKE JASON · SPEAKE JASON D · SPEAKE JASON DANIEL
32 granted patents·16 pending applications·67 citations·filing 2000–2022
96Inventor score
Files withAVISTA PHARMA SOLUTIONS INC17TARGACEPT INC6CATALYST BIOSCIENCES INC3GLAXOSMITHKLINE LLC3AKIREDDY SRINIVASA RAO2
Top patents by PatentIndex Score
48 records- 0188US9420793B2Antiparasitic compoundsAvista Pharma Solutions·Filed 2016·Granted Aug 23, 2016·7 cites·2 claims
- 0285US9686991B2Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2016·Granted Jun 27, 2017·4 cites·18 claims
- 0383US10258582B2Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2018·Granted Apr 16, 2019·2 cites·3 claims
- 0483US8809397B2Nicotinic receptor non-competitive antagonistsAKIREDDY SRINIVASA RAO·Filed 2011·Granted Aug 19, 2014·5 cites·10 claims
- 0582US7442693B2Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptorsSMITHKLINE BEECHAM CORP·Filed 2005·Granted Oct 28, 2008·7 cites·3 claims
- 0681US10092001B2Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2017·Granted Oct 9, 2018·2 cites·6 claims
- 0780US9883674B2Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2017·Granted Feb 6, 2018·2 cites·5 claims
- 0880US9532974B2Nicotinic receptor non-competitive antagonistsTARGACEPT INC·Filed 2015·Granted Jan 3, 2017·2 cites·2 claims
- 0980US7285557B2Pyrimidinones as melanin concentrating hormone receptor 1SMITHKLINE BEECHAM PLC·Filed 2002·Granted Oct 23, 2007·15 cites·25 claims
- 1079US10772331B2Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2019·Granted Sep 15, 2020·0 cites·24 claims
- 1179US8901151B2Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamideTARGACEPT INC·Filed 2013·Granted Dec 2, 2014·3 cites·1 claims
- 1277US8476296B2Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamideBENCHERIF MEROUANE·Filed 2010·Granted Jul 2, 2013·4 cites·15 claims
- 1374US7368453B2Quinazolinone compounds with reduced bioaccumulationCHIRON CORP·Filed 2004·Granted May 6, 2008·7 cites·23 claims
- 1472US10961261B2Oxaborole analogs and uses thereofANACOR PHARMACEUTICALS INC·Filed 2018·Granted Mar 30, 2021·1 cites·20 claims
- 1572US10716770B2Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2019·Granted Jul 21, 2020·0 cites·5 claims
- 1671US9173876B2Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamideTARGACEPT INC·Filed 2014·Granted Nov 3, 2015·1 cites·1 claims
- 1770US8633175B2Compounds as antagonists or inverse agonists at opioid receptorsCOWAN DAVID JOHN·Filed 2007·Granted Jan 21, 2014·2 cites·9 claims
- 1868US11691992B2Oxaborole analogs and uses thereofANACOR PHARMACEUTICALS INC·Filed 2021·Granted Jul 4, 2023·0 cites·20 claims
- 1968US10570144B2Substituted ureas as prostaglandin EP4 receptor antagonistsAVISTA PHARMA SOLUTIONS INC·Filed 2019·Granted Feb 25, 2020·0 cites·22 claims
- 2067US10239885B1Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonistAVISTA PHARMA SOLUTIONS INC·Filed 2018·Granted Mar 26, 2019·0 cites·2 claims
- 2167US2023100692A1Synthetic process and novel intermediatesAVISTA PHARMA SOLUTIONS INC·Filed 2022·Application pending·0 cites
- 2266US10342234B2Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2018·Granted Jul 9, 2019·0 cites·14 claims
- 2366US2023029009A1Chemical compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2022·Application pending·0 cites
- 2465US9643963B2Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2014·Granted May 9, 2017·0 cites·13 claims
- 2564US2014315877A1Nicotinic receptor non-competitive antagonistsTARGACEPT INC·Filed 2014·Application pending·0 cites
- 2663US11512088B2Synthetic process and intermediatesAVISTA PHARMA SOLUTIONS INC·Filed 2020·Granted Nov 29, 2022·0 cites·7 claims
- 2763US2024365736A1Compositions and methods for targeted degradation of proteins in a plant cellOERTH BIO LLC·Filed 2022·Application pending·0 cites
- 2861US10744136B2Sulfonamide derivatives as JAK inhibitorsAVISTA PHARMA SOLUTIONS INC·Filed 2019·Granted Aug 18, 2020·0 cites·6 claims
- 2961US10556909B2Synthetic process and intermediatesAVISTA PHARMA SOLUTIONS INC·Filed 2017·Granted Feb 11, 2020·0 cites·20 claims
- 3061US2020148693A1Chemical CompoundsAVISTA PHARMA SOLUTIONS INC·Filed 2020·Application pending·0 cites
- 3160US6884801B1Imidazoline derivatives as alpha-1A adrenoceptor ligandsSMITHKLINE BEECHAM CORP·Filed 2000·Granted Apr 26, 2005·2 cites·21 claims
- 3259US8822518B2Compounds as antagonists or inverse agonists of opioid receptors for treatment of addictionGLAXOSMITHKLINE LLC·Filed 2013·Granted Sep 2, 2014·0 cites·10 claims
- 3359US7625909B2Substituted quinazolinone compoundsNOVARTIS VACCINES & DIAGNOSTIC·Filed 2004·Granted Dec 1, 2009·1 cites·21 claims
- 3459US2017071878A1Nicotinic receptor non-competitive antagonistsCATALYST BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 3558US11459331B2Chemical compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2020·Granted Oct 4, 2022·0 cites·23 claims
- 3655US2014323487A1Novel Compounds As Antagonists Or Inverse Agonists At Opioid ReceptorsGLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 3752US2017202849A1Antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2017·Application pending·0 cites
- 3851US2011263629A1Amides of diazabicyclooctanes and uses thereofTARGACEPT INC·Filed 2009·Application pending·0 cites
- 3950US2010105654A1Substituted quinazolinone compoundsBOYCE RUSTUM S·Filed 2009·Application pending·0 cites
- 4049US2020181134A1Antiparasitic CompoundsAVISTA PHAMA SOLUTIONS INC·Filed 2017·Application pending·0 cites
- 4147US10807992B2Single enantiomer antiparasitic compoundsAVISTA PHARMA SOLUTIONS INC·Filed 2018·Granted Oct 20, 2020·0 cites·33 claims
- 4247US2017119746A1Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamideATTENUA INC·Filed 2015·Application pending·0 cites
- 4345US7939528B2Heterocycle compoundsGLAXOSMITHKLINE LLC·Filed 2006·Granted May 10, 2011·0 cites·13 claims
- 4441US2014288185A1Nicotinic receptor non-competitive modulatorsTARGACEPT INC·Filed 2012·Application pending·0 cites
- 4540US2010222345A1Novel compounds as antagonists or inverse agonists for opioid receptorsDIAZ CAROLINE JEAN·Filed 2007·Application pending·0 cites
- 4638US2006194871A1Heterocyclic mchr1 antagoistsBARVIAN KEVIN K·Filed 2004·Application pending·0 cites
- 4737US2014288169A1Nicotinic receptor non-competitive antagonistsAKIREDDY SRINIVASA RAO·Filed 2012·Application pending·0 cites
- 4832US11220507B2Process for the preparation of rucaparib and novel synthesis intermediatesADVITECH ADVISORY AND TECH SA·Filed 2017·Granted Jan 11, 2022·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Jason D. Speake files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →